Daewoong Pharmaceutical, Stock Price +29.95% at This Time... 14,216 Shares Net Sold by Individuals in the Last 5 Days

Daewoong Pharmaceutical is trading at 275,500 KRW as of 1:30 PM on the 21st, up 29.95% from the previous day. The trading volume is 309,692 shares, which is 5.34% of the previous day's volume. Daewoong Pharmaceutical is known as a leading pharmaceutical company manufacturing and selling drugs such as Urusa and Albis.

On December 17, researcher Lee Hye-rin from KTB Investment & Securities stated, "After the US market closed early morning, the ITC final ruling was announced. A 21-month import ban order was issued. The market had already reflected the worst-case scenario of the ITC lawsuit, so this is considered a positive issue. The preliminary ruling of a 10-year import ban was the worst case, and as a result, the value of Nabota's export business was reflected as zero when calculating Daewoong Pharmaceutical's target price. If the final ruling does not overturn the result, the punitive damages portion from Evolus would have to be considered, and this risk was factored into the target price." He set Daewoong Pharmaceutical's target price at 130,000 KRW.

Over the past five days, individual investors have net sold 14,216 shares of Daewoong Pharmaceutical, while foreigners and institutions have net bought 7,345 shares and 13,214 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.